secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001662774-24-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline
--------------------------------------------------------------------------------

- Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.
- Net loss $27.7M ($0.64/share) includes $17.1M goodwill impairment; R&D $4.2M, G&A $4.7M.
- Phase 3 NEAT enrolled 7 patients; topline results expected Q4 2025; NDA/MAA in 2026 if positive.
- FDA Fast Track for EryDex in A-T; diagnosed U.S. patients estimated at ~4,600 (up from ~3,400).
- Planning DMD proof-of-concept study in 2025; evaluating partnerships for ex-U.S. rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000166277424000004/0001662774-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000166277424000004/qncx-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001662774-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer